 Jeremy Prager
Concepts (421)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Trachea | 13 | 2022 | 237 | 2.880 |
Why?
| | Tonsillectomy | 5 | 2025 | 89 | 2.330 |
Why?
| | Otolaryngology | 7 | 2022 | 96 | 1.940 |
Why?
| | Laryngoscopy | 8 | 2024 | 109 | 1.680 |
Why?
| | Tracheal Stenosis | 6 | 2023 | 31 | 1.610 |
Why?
| | Respiratory Tract Diseases | 4 | 2019 | 184 | 1.590 |
Why?
| | Bronchoscopy | 12 | 2021 | 223 | 1.420 |
Why?
| | Larynx | 4 | 2024 | 60 | 1.270 |
Why?
| | Tracheomalacia | 4 | 2022 | 17 | 1.210 |
Why?
| | Correspondence as Topic | 3 | 2012 | 15 | 1.110 |
Why?
| | Deglutition Disorders | 4 | 2023 | 143 | 0.970 |
Why?
| | Postoperative Nausea and Vomiting | 1 | 2025 | 16 | 0.970 |
Why?
| | Laryngostenosis | 3 | 2023 | 51 | 0.970 |
Why?
| | Papilloma | 1 | 2025 | 52 | 0.950 |
Why?
| | Respiratory Distress Syndrome, Newborn | 2 | 2018 | 106 | 0.940 |
Why?
| | Otitis Media | 7 | 2023 | 165 | 0.940 |
Why?
| | Antiemetics | 1 | 2025 | 43 | 0.940 |
Why?
| | Oropharyngeal Neoplasms | 1 | 2025 | 63 | 0.910 |
Why?
| | Mouth Neoplasms | 1 | 2025 | 120 | 0.870 |
Why?
| | Child | 54 | 2025 | 21819 | 0.870 |
Why?
| | Airway Obstruction | 6 | 2021 | 162 | 0.860 |
Why?
| | Papillomavirus Infections | 3 | 2025 | 324 | 0.860 |
Why?
| | Esophagoscopy | 4 | 2020 | 209 | 0.840 |
Why?
| | Efficiency, Organizational | 4 | 2019 | 139 | 0.820 |
Why?
| | Dexamethasone | 1 | 2025 | 368 | 0.810 |
Why?
| | Operating Rooms | 2 | 2015 | 123 | 0.800 |
Why?
| | Gastrointestinal Diseases | 3 | 2019 | 209 | 0.780 |
Why?
| | Otorhinolaryngologic Surgical Procedures | 3 | 2021 | 40 | 0.750 |
Why?
| | Adenoidectomy | 4 | 2021 | 72 | 0.750 |
Why?
| | Otorhinolaryngologic Diseases | 2 | 2019 | 16 | 0.730 |
Why?
| | Polytetrafluoroethylene | 1 | 2021 | 23 | 0.730 |
Why?
| | Respiratory Sounds | 2 | 2018 | 125 | 0.690 |
Why?
| | Abscess | 1 | 2020 | 74 | 0.660 |
Why?
| | Congenital Abnormalities | 2 | 2024 | 88 | 0.650 |
Why?
| | Ancillary Services, Hospital | 1 | 2019 | 2 | 0.640 |
Why?
| | Child, Preschool | 32 | 2025 | 10997 | 0.640 |
Why?
| | Hospitals, Pediatric | 6 | 2020 | 505 | 0.630 |
Why?
| | Hematologic Neoplasms | 1 | 2021 | 155 | 0.630 |
Why?
| | Internship and Residency | 4 | 2020 | 1133 | 0.620 |
Why?
| | Digestive System Diseases | 1 | 2019 | 26 | 0.620 |
Why?
| | Patient Care Team | 3 | 2019 | 626 | 0.610 |
Why?
| | Helicobacter Infections | 1 | 2018 | 32 | 0.600 |
Why?
| | Helicobacter pylori | 1 | 2018 | 42 | 0.600 |
Why?
| | Craniocerebral Trauma | 1 | 2020 | 167 | 0.590 |
Why?
| | Humans | 84 | 2025 | 136803 | 0.580 |
Why?
| | Tracheal Neoplasms | 1 | 2018 | 9 | 0.580 |
Why?
| | Intubation, Intratracheal | 3 | 2015 | 257 | 0.580 |
Why?
| | Tracheostomy | 2 | 2019 | 132 | 0.570 |
Why?
| | Eosinophilic Esophagitis | 3 | 2019 | 325 | 0.560 |
Why?
| | Paraganglioma | 1 | 2018 | 52 | 0.530 |
Why?
| | Quality Improvement | 3 | 2016 | 1163 | 0.510 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2019 | 255 | 0.490 |
Why?
| | Male | 47 | 2025 | 67330 | 0.490 |
Why?
| | Retrospective Studies | 24 | 2025 | 15510 | 0.490 |
Why?
| | Gastroesophageal Reflux | 4 | 2023 | 234 | 0.490 |
Why?
| | Tracheoesophageal Fistula | 3 | 2022 | 33 | 0.480 |
Why?
| | Clinical Competence | 4 | 2020 | 1094 | 0.470 |
Why?
| | Natural Orifice Endoscopic Surgery | 1 | 2015 | 34 | 0.470 |
Why?
| | Patient Satisfaction | 2 | 2019 | 656 | 0.460 |
Why?
| | Gastroenterology | 3 | 2023 | 181 | 0.460 |
Why?
| | Spinal Fractures | 1 | 2015 | 73 | 0.460 |
Why?
| | Infant | 22 | 2024 | 9395 | 0.460 |
Why?
| | Phenol | 1 | 2014 | 19 | 0.450 |
Why?
| | Drug Labeling | 1 | 2014 | 39 | 0.440 |
Why?
| | Delphi Technique | 8 | 2024 | 273 | 0.440 |
Why?
| | Anti-Infective Agents, Local | 1 | 2014 | 40 | 0.440 |
Why?
| | Burns, Chemical | 1 | 2014 | 32 | 0.440 |
Why?
| | Postoperative Complications | 6 | 2022 | 2639 | 0.430 |
Why?
| | Medical Audit | 1 | 2014 | 78 | 0.430 |
Why?
| | Female | 43 | 2025 | 72816 | 0.420 |
Why?
| | Chromosome Disorders | 1 | 2013 | 43 | 0.420 |
Why?
| | Consensus | 7 | 2024 | 678 | 0.410 |
Why?
| | Thyroid Neoplasms | 3 | 2023 | 337 | 0.400 |
Why?
| | Career Choice | 2 | 2011 | 216 | 0.390 |
Why?
| | Wounds, Nonpenetrating | 1 | 2015 | 276 | 0.390 |
Why?
| | Sleep Apnea Syndromes | 1 | 2013 | 88 | 0.380 |
Why?
| | Abnormalities, Multiple | 1 | 2013 | 188 | 0.370 |
Why?
| | Student Dropouts | 1 | 2011 | 8 | 0.370 |
Why?
| | Adolescent | 25 | 2025 | 21385 | 0.360 |
Why?
| | Writing | 1 | 2012 | 94 | 0.360 |
Why?
| | Job Description | 1 | 2010 | 14 | 0.350 |
Why?
| | Deafness | 1 | 2012 | 77 | 0.350 |
Why?
| | Pharyngeal Diseases | 1 | 2010 | 16 | 0.350 |
Why?
| | Cochlear Implantation | 1 | 2012 | 76 | 0.350 |
Why?
| | Minimally Invasive Surgical Procedures | 1 | 2012 | 179 | 0.350 |
Why?
| | Endoscopy, Gastrointestinal | 2 | 2024 | 228 | 0.340 |
Why?
| | Education, Medical, Continuing | 1 | 2011 | 127 | 0.340 |
Why?
| | Pediatrics | 4 | 2019 | 1094 | 0.340 |
Why?
| | School Admission Criteria | 1 | 2010 | 27 | 0.340 |
Why?
| | Pain, Postoperative | 2 | 2025 | 266 | 0.340 |
Why?
| | Pulmonary Embolism | 1 | 2013 | 225 | 0.340 |
Why?
| | Bronchiectasis | 3 | 2020 | 111 | 0.330 |
Why?
| | Fucosyltransferases | 2 | 2022 | 33 | 0.330 |
Why?
| | Intestinal Mucosa | 1 | 2015 | 621 | 0.330 |
Why?
| | Personnel Selection | 1 | 2010 | 78 | 0.320 |
Why?
| | Tracheotomy | 4 | 2019 | 23 | 0.310 |
Why?
| | Palatine Tonsil | 2 | 2021 | 48 | 0.300 |
Why?
| | Thoracoscopy | 2 | 2019 | 56 | 0.300 |
Why?
| | Microbiota | 5 | 2023 | 762 | 0.290 |
Why?
| | Infant, Newborn | 8 | 2023 | 6032 | 0.290 |
Why?
| | Esophageal Atresia | 2 | 2020 | 26 | 0.290 |
Why?
| | Anesthesia | 2 | 2023 | 189 | 0.290 |
Why?
| | Hearing Loss, Conductive | 1 | 2007 | 22 | 0.280 |
Why?
| | Faculty, Medical | 1 | 2010 | 283 | 0.270 |
Why?
| | Craniosynostoses | 1 | 2007 | 57 | 0.270 |
Why?
| | Ear, Middle | 5 | 2023 | 85 | 0.260 |
Why?
| | Treatment Outcome | 9 | 2024 | 10748 | 0.260 |
Why?
| | Program Development | 2 | 2019 | 364 | 0.250 |
Why?
| | Deglutition | 2 | 2024 | 72 | 0.250 |
Why?
| | Surgeons | 2 | 2020 | 296 | 0.250 |
Why?
| | Down Syndrome | 2 | 2023 | 490 | 0.240 |
Why?
| | Practice Guidelines as Topic | 2 | 2018 | 1572 | 0.230 |
Why?
| | Tracheobronchomalacia | 2 | 2022 | 14 | 0.230 |
Why?
| | Administration, Intravenous | 1 | 2025 | 155 | 0.230 |
Why?
| | Biopsy | 3 | 2019 | 1124 | 0.230 |
Why?
| | Nasal Septal Perforation | 1 | 2024 | 4 | 0.230 |
Why?
| | Respiratory Tract Infections | 3 | 2021 | 394 | 0.230 |
Why?
| | Fascia | 1 | 2024 | 17 | 0.220 |
Why?
| | Papillomaviridae | 1 | 2025 | 126 | 0.220 |
Why?
| | Sutures | 2 | 2021 | 58 | 0.220 |
Why?
| | Multiple Endocrine Neoplasia | 1 | 2023 | 5 | 0.210 |
Why?
| | Multiple Endocrine Neoplasia Type 2b | 1 | 2023 | 6 | 0.210 |
Why?
| | Multiple Endocrine Neoplasia Type 2a | 1 | 2023 | 9 | 0.210 |
Why?
| | Croup | 1 | 2023 | 19 | 0.200 |
Why?
| | Membrane Proteins | 2 | 2021 | 1163 | 0.200 |
Why?
| | Administration, Oral | 1 | 2025 | 813 | 0.200 |
Why?
| | Prospective Studies | 5 | 2025 | 7573 | 0.200 |
Why?
| | Vocal Cord Dysfunction | 1 | 2022 | 10 | 0.200 |
Why?
| | Hypoparathyroidism | 1 | 2022 | 4 | 0.190 |
Why?
| | Recurrent Laryngeal Nerve Injuries | 1 | 2022 | 12 | 0.190 |
Why?
| | Laryngoscopes | 1 | 2022 | 38 | 0.190 |
Why?
| | Colorado | 5 | 2020 | 4515 | 0.190 |
Why?
| | Graves Disease | 1 | 2022 | 34 | 0.190 |
Why?
| | Constriction, Pathologic | 4 | 2023 | 242 | 0.180 |
Why?
| | Cadherin Related Proteins | 1 | 2021 | 14 | 0.180 |
Why?
| | Haemophilus Infections | 1 | 2022 | 42 | 0.180 |
Why?
| | Nasopharynx | 1 | 2022 | 76 | 0.180 |
Why?
| | Medicine | 1 | 2023 | 121 | 0.180 |
Why?
| | Acrocephalosyndactylia | 1 | 2021 | 10 | 0.180 |
Why?
| | Nasal Obstruction | 1 | 2021 | 27 | 0.170 |
Why?
| | Job Satisfaction | 1 | 2023 | 217 | 0.170 |
Why?
| | Nasal Septum | 1 | 2020 | 25 | 0.170 |
Why?
| | Double-Blind Method | 1 | 2025 | 1982 | 0.170 |
Why?
| | Plasminogen | 1 | 2020 | 30 | 0.170 |
Why?
| | Hematoma | 1 | 2020 | 53 | 0.170 |
Why?
| | Mucolipidoses | 1 | 2020 | 7 | 0.170 |
Why?
| | Bevacizumab | 1 | 2021 | 135 | 0.170 |
Why?
| | Follow-Up Studies | 7 | 2019 | 5106 | 0.160 |
Why?
| | Bone Marrow Transplantation | 4 | 1997 | 287 | 0.160 |
Why?
| | Respiratory Tract Fistula | 1 | 2019 | 7 | 0.160 |
Why?
| | Cutaneous Fistula | 1 | 2019 | 14 | 0.160 |
Why?
| | Tracheal Diseases | 1 | 2019 | 15 | 0.160 |
Why?
| | Cartilage | 1 | 2021 | 188 | 0.160 |
Why?
| | Arytenoid Cartilage | 1 | 2019 | 7 | 0.160 |
Why?
| | alpha-Macroglobulins | 1 | 2019 | 24 | 0.160 |
Why?
| | Angiogenesis Inhibitors | 1 | 2021 | 226 | 0.150 |
Why?
| | Speech-Language Pathology | 1 | 2019 | 24 | 0.150 |
Why?
| | Laryngomalacia | 1 | 2018 | 5 | 0.150 |
Why?
| | Registries | 2 | 2024 | 2015 | 0.150 |
Why?
| | Chemoreceptor Cells | 1 | 2019 | 51 | 0.150 |
Why?
| | Laryngoplasty | 1 | 2018 | 6 | 0.150 |
Why?
| | Young Adult | 9 | 2024 | 13129 | 0.150 |
Why?
| | Airway Extubation | 1 | 2019 | 57 | 0.150 |
Why?
| | Models, Organizational | 1 | 2019 | 150 | 0.150 |
Why?
| | Mutation, Missense | 1 | 2020 | 337 | 0.150 |
Why?
| | Pulmonary Medicine | 1 | 2019 | 85 | 0.150 |
Why?
| | Interdisciplinary Communication | 1 | 2019 | 191 | 0.140 |
Why?
| | United States | 7 | 2019 | 14691 | 0.140 |
Why?
| | Respiratory System | 1 | 2019 | 157 | 0.140 |
Why?
| | Vascular Diseases | 1 | 2020 | 243 | 0.140 |
Why?
| | Respiration Disorders | 1 | 2018 | 77 | 0.140 |
Why?
| | Esophageal Mucosa | 1 | 2018 | 22 | 0.140 |
Why?
| | Child Behavior | 1 | 2020 | 246 | 0.140 |
Why?
| | Virtual Reality | 1 | 2019 | 61 | 0.140 |
Why?
| | Severity of Illness Index | 4 | 2016 | 2822 | 0.140 |
Why?
| | Proton Pump Inhibitors | 1 | 2018 | 109 | 0.140 |
Why?
| | Carcinoma, Medullary | 1 | 2017 | 17 | 0.140 |
Why?
| | Betacoronavirus | 1 | 2020 | 266 | 0.130 |
Why?
| | Bronchopulmonary Dysplasia | 1 | 2022 | 382 | 0.130 |
Why?
| | Reoperation | 2 | 2018 | 573 | 0.130 |
Why?
| | Down-Regulation | 1 | 2019 | 656 | 0.130 |
Why?
| | Gastrostomy | 1 | 2018 | 112 | 0.130 |
Why?
| | Burnout, Professional | 1 | 2023 | 441 | 0.130 |
Why?
| | Cost-Benefit Analysis | 1 | 2019 | 587 | 0.130 |
Why?
| | Sequence Analysis, DNA | 1 | 2019 | 809 | 0.120 |
Why?
| | Neuromuscular Nondepolarizing Agents | 1 | 2015 | 17 | 0.120 |
Why?
| | Androstanols | 1 | 2015 | 18 | 0.120 |
Why?
| | Anesthetics, Intravenous | 1 | 2015 | 47 | 0.120 |
Why?
| | RNA, Ribosomal, 16S | 3 | 2023 | 549 | 0.120 |
Why?
| | Midazolam | 1 | 2015 | 56 | 0.120 |
Why?
| | Genetic Predisposition to Disease | 3 | 2021 | 2412 | 0.120 |
Why?
| | Clinical Audit | 1 | 2015 | 13 | 0.120 |
Why?
| | Time and Motion Studies | 1 | 2015 | 25 | 0.120 |
Why?
| | Surveys and Questionnaires | 5 | 2024 | 5744 | 0.120 |
Why?
| | Mouth | 1 | 2015 | 87 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 368 | 0.120 |
Why?
| | Coronavirus Infections | 1 | 2020 | 358 | 0.120 |
Why?
| | Esophagus | 3 | 2024 | 255 | 0.110 |
Why?
| | Reproducibility of Results | 3 | 2024 | 3265 | 0.110 |
Why?
| | DNA, Recombinant | 1 | 2014 | 47 | 0.110 |
Why?
| | Fentanyl | 1 | 2015 | 94 | 0.110 |
Why?
| | Program Evaluation | 1 | 2019 | 889 | 0.110 |
Why?
| | Respiratory Aspiration | 1 | 2014 | 31 | 0.110 |
Why?
| | Prognosis | 3 | 2018 | 4013 | 0.110 |
Why?
| | Tomography, X-Ray Computed | 3 | 2020 | 2668 | 0.110 |
Why?
| | Survival Rate | 2 | 2018 | 1964 | 0.110 |
Why?
| | Administration, Intranasal | 1 | 2014 | 89 | 0.110 |
Why?
| | Quality of Health Care | 1 | 2019 | 634 | 0.110 |
Why?
| | Pedigree | 3 | 2020 | 514 | 0.110 |
Why?
| | Bronchogenic Cyst | 1 | 2013 | 7 | 0.110 |
Why?
| | Iatrogenic Disease | 1 | 2014 | 66 | 0.110 |
Why?
| | Anesthetics, Local | 1 | 2014 | 80 | 0.110 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 2013 | 71 | 0.100 |
Why?
| | Ambulatory Care | 1 | 2018 | 539 | 0.100 |
Why?
| | Patient Outcome Assessment | 1 | 2014 | 131 | 0.100 |
Why?
| | Chromosome Deletion | 1 | 2013 | 115 | 0.100 |
Why?
| | Appointments and Schedules | 1 | 2014 | 89 | 0.100 |
Why?
| | Genetic Variation | 1 | 2018 | 985 | 0.100 |
Why?
| | Radiography | 1 | 2015 | 822 | 0.100 |
Why?
| | Pharyngitis | 1 | 2013 | 26 | 0.100 |
Why?
| | Rhinitis | 1 | 2014 | 158 | 0.100 |
Why?
| | Neuralgia | 1 | 2014 | 133 | 0.100 |
Why?
| | Tetanus Antitoxin | 1 | 1992 | 3 | 0.100 |
Why?
| | Tetanus Toxoid | 1 | 1992 | 35 | 0.100 |
Why?
| | Antibodies | 1 | 2014 | 411 | 0.100 |
Why?
| | Fatal Outcome | 1 | 2013 | 303 | 0.090 |
Why?
| | Immunization, Secondary | 1 | 1992 | 89 | 0.090 |
Why?
| | Graft Rejection | 1 | 2016 | 620 | 0.090 |
Why?
| | Gene Expression Profiling | 1 | 2019 | 1772 | 0.090 |
Why?
| | Academic Medical Centers | 1 | 2015 | 504 | 0.090 |
Why?
| | Sinusitis | 1 | 2014 | 221 | 0.090 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2014 | 543 | 0.090 |
Why?
| | Mutation | 2 | 2021 | 3947 | 0.090 |
Why?
| | Patient Safety | 1 | 2015 | 308 | 0.090 |
Why?
| | Pandemics | 1 | 2020 | 1616 | 0.090 |
Why?
| | Cytosine | 1 | 2011 | 49 | 0.090 |
Why?
| | Time Factors | 3 | 2019 | 6809 | 0.090 |
Why?
| | Off-Label Use | 1 | 2011 | 51 | 0.090 |
Why?
| | Ear Ossicles | 1 | 2010 | 11 | 0.090 |
Why?
| | Airway Management | 1 | 2011 | 52 | 0.080 |
Why?
| | Patient Readmission | 1 | 2016 | 694 | 0.080 |
Why?
| | Organophosphonates | 1 | 2011 | 93 | 0.080 |
Why?
| | Endoscopy, Digestive System | 2 | 2024 | 136 | 0.080 |
Why?
| | Referral and Consultation | 1 | 2015 | 780 | 0.080 |
Why?
| | Professional Competence | 1 | 2010 | 100 | 0.080 |
Why?
| | Teratoma | 1 | 2011 | 114 | 0.080 |
Why?
| | Disclosure | 1 | 2010 | 112 | 0.080 |
Why?
| | Asthma | 1 | 2023 | 2282 | 0.080 |
Why?
| | Thyroidectomy | 2 | 2022 | 106 | 0.080 |
Why?
| | Communication | 1 | 2015 | 875 | 0.080 |
Why?
| | Hospitalization | 1 | 2018 | 2184 | 0.070 |
Why?
| | Patient Selection | 1 | 2012 | 691 | 0.070 |
Why?
| | Electronic Health Records | 1 | 2016 | 1046 | 0.070 |
Why?
| | Magnetic Resonance Imaging | 2 | 2018 | 3556 | 0.070 |
Why?
| | Middle Ear Ventilation | 1 | 2007 | 15 | 0.070 |
Why?
| | Mice | 6 | 2022 | 17759 | 0.070 |
Why?
| | Audiometry | 1 | 2007 | 26 | 0.070 |
Why?
| | Prevalence | 2 | 2020 | 2710 | 0.070 |
Why?
| | RNA, Messenger | 1 | 2014 | 2831 | 0.060 |
Why?
| | Antiviral Agents | 2 | 2011 | 739 | 0.060 |
Why?
| | Risk Factors | 3 | 2019 | 10332 | 0.060 |
Why?
| | Hematologic Diseases | 1 | 1986 | 62 | 0.060 |
Why?
| | Catheters, Indwelling | 1 | 1986 | 91 | 0.060 |
Why?
| | Pilot Projects | 1 | 2010 | 1693 | 0.060 |
Why?
| | Head and Neck Neoplasms | 1 | 2011 | 604 | 0.060 |
Why?
| | Practice Patterns, Physicians' | 1 | 2014 | 1301 | 0.060 |
Why?
| | Temporal Muscle | 1 | 2024 | 3 | 0.060 |
Why?
| | Cadaver | 2 | 2019 | 296 | 0.060 |
Why?
| | Absorbable Implants | 1 | 2024 | 35 | 0.060 |
Why?
| | Polyesters | 1 | 2024 | 76 | 0.050 |
Why?
| | Video Recording | 1 | 2024 | 180 | 0.050 |
Why?
| | Observer Variation | 1 | 2024 | 341 | 0.050 |
Why?
| | Transplantation, Homologous | 4 | 2011 | 415 | 0.050 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2023 | 42 | 0.050 |
Why?
| | Hyperplasia | 1 | 2023 | 175 | 0.050 |
Why?
| | Animals | 6 | 2022 | 36850 | 0.050 |
Why?
| | Breathing Exercises | 1 | 2022 | 21 | 0.050 |
Why?
| | Vocal Cords | 1 | 2022 | 32 | 0.050 |
Why?
| | Cough | 1 | 2023 | 122 | 0.050 |
Why?
| | Biofeedback, Psychology | 1 | 2022 | 37 | 0.050 |
Why?
| | Haemophilus influenzae | 1 | 2022 | 63 | 0.050 |
Why?
| | Bayes Theorem | 1 | 2023 | 404 | 0.040 |
Why?
| | Leukemia, Myeloid, Acute | 3 | 1992 | 622 | 0.040 |
Why?
| | Esophagoscopes | 1 | 2020 | 5 | 0.040 |
Why?
| | Nasal Cavity | 1 | 2021 | 52 | 0.040 |
Why?
| | Perioperative Period | 1 | 2020 | 56 | 0.040 |
Why?
| | Internationality | 1 | 2021 | 154 | 0.040 |
Why?
| | Antineoplastic Agents | 1 | 2011 | 2123 | 0.040 |
Why?
| | Philippines | 1 | 2019 | 51 | 0.040 |
Why?
| | Laryngeal Mucosa | 1 | 2019 | 8 | 0.040 |
Why?
| | Adrenal Cortex Hormones | 1 | 2023 | 556 | 0.040 |
Why?
| | Pakistan | 1 | 2019 | 76 | 0.040 |
Why?
| | Foreign Bodies | 1 | 2020 | 104 | 0.040 |
Why?
| | Finland | 1 | 2019 | 85 | 0.040 |
Why?
| | Mice, Inbred C57BL | 2 | 2021 | 5750 | 0.040 |
Why?
| | Single-Blind Method | 1 | 2019 | 282 | 0.040 |
Why?
| | Lung | 2 | 2023 | 4063 | 0.040 |
Why?
| | Social Support | 1 | 2023 | 616 | 0.040 |
Why?
| | Esophageal pH Monitoring | 1 | 2018 | 23 | 0.040 |
Why?
| | Saliva | 1 | 2020 | 242 | 0.040 |
Why?
| | California | 1 | 2020 | 429 | 0.040 |
Why?
| | Clinical Protocols | 1 | 2020 | 267 | 0.040 |
Why?
| | Nerve Fibers | 1 | 2019 | 96 | 0.040 |
Why?
| | Patient Reported Outcome Measures | 1 | 2022 | 402 | 0.040 |
Why?
| | COS Cells | 1 | 2018 | 188 | 0.040 |
Why?
| | Electric Impedance | 1 | 2018 | 107 | 0.040 |
Why?
| | Device Removal | 1 | 2019 | 136 | 0.040 |
Why?
| | Emotions | 1 | 2023 | 545 | 0.040 |
Why?
| | Interdisciplinary Research | 1 | 2018 | 27 | 0.040 |
Why?
| | Infant, Premature | 1 | 2022 | 566 | 0.040 |
Why?
| | Anesthetics | 1 | 2018 | 81 | 0.030 |
Why?
| | Exome | 1 | 2018 | 230 | 0.030 |
Why?
| | Chickenpox Vaccine | 1 | 1997 | 73 | 0.030 |
Why?
| | Transplantation, Autologous | 3 | 1992 | 238 | 0.030 |
Why?
| | Ultrasonography, Doppler | 1 | 2017 | 123 | 0.030 |
Why?
| | Ambulatory Care Facilities | 1 | 2018 | 231 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2019 | 452 | 0.030 |
Why?
| | Perioperative Care | 1 | 2018 | 178 | 0.030 |
Why?
| | Terminology as Topic | 1 | 2018 | 216 | 0.030 |
Why?
| | Survival Analysis | 2 | 2017 | 1321 | 0.030 |
Why?
| | Taste Buds | 1 | 2019 | 208 | 0.030 |
Why?
| | Recurrence | 1 | 2019 | 1055 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2018 | 729 | 0.030 |
Why?
| | Patient-Centered Care | 1 | 2021 | 522 | 0.030 |
Why?
| | Comorbidity | 1 | 2020 | 1614 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2017 | 686 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2017 | 507 | 0.030 |
Why?
| | Age Factors | 2 | 2014 | 3286 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2019 | 951 | 0.030 |
Why?
| | Tongue | 1 | 2015 | 81 | 0.030 |
Why?
| | Health Services Research | 1 | 2018 | 400 | 0.030 |
Why?
| | Hypertrophy | 1 | 2015 | 133 | 0.030 |
Why?
| | Genomics | 1 | 2020 | 790 | 0.030 |
Why?
| | Transcriptome | 1 | 2021 | 969 | 0.030 |
Why?
| | Long-Term Care | 1 | 2015 | 106 | 0.030 |
Why?
| | Adolescent Behavior | 1 | 2020 | 529 | 0.030 |
Why?
| | Disease Management | 1 | 2019 | 624 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2019 | 1733 | 0.030 |
Why?
| | Benzofurans | 1 | 2014 | 21 | 0.030 |
Why?
| | Pain Threshold | 1 | 2014 | 74 | 0.030 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2020 | 614 | 0.030 |
Why?
| | Neural Conduction | 1 | 2014 | 86 | 0.030 |
Why?
| | TRPV Cation Channels | 1 | 2014 | 40 | 0.030 |
Why?
| | Ganglia, Spinal | 1 | 2014 | 77 | 0.030 |
Why?
| | Sensory Receptor Cells | 1 | 2014 | 98 | 0.030 |
Why?
| | Thoracotomy | 1 | 2013 | 75 | 0.030 |
Why?
| | Hyperalgesia | 1 | 2014 | 123 | 0.030 |
Why?
| | Neoplasm Staging | 1 | 2017 | 1373 | 0.030 |
Why?
| | Fetal Therapies | 1 | 2013 | 40 | 0.030 |
Why?
| | Quinolines | 1 | 2014 | 177 | 0.030 |
Why?
| | Rats, Wistar | 1 | 2014 | 455 | 0.030 |
Why?
| | Cell Line | 1 | 2018 | 2838 | 0.020 |
Why?
| | Early Detection of Cancer | 1 | 2017 | 417 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2020 | 2184 | 0.020 |
Why?
| | Adult | 5 | 2023 | 37643 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2020 | 2829 | 0.020 |
Why?
| | Tetanus | 1 | 1992 | 25 | 0.020 |
Why?
| | Anemia, Aplastic | 1 | 1992 | 38 | 0.020 |
Why?
| | Pain Measurement | 1 | 2014 | 521 | 0.020 |
Why?
| | Endoscopy | 1 | 2014 | 318 | 0.020 |
Why?
| | Ultrasonography, Prenatal | 1 | 2013 | 284 | 0.020 |
Why?
| | Cohort Studies | 1 | 2022 | 5704 | 0.020 |
Why?
| | Injections, Intralesional | 1 | 2011 | 34 | 0.020 |
Why?
| | Neoplasms | 1 | 1986 | 2643 | 0.020 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2015 | 291 | 0.020 |
Why?
| | Enzyme Inhibitors | 1 | 2014 | 839 | 0.020 |
Why?
| | Malleus | 1 | 2010 | 1 | 0.020 |
Why?
| | Incus | 1 | 2010 | 6 | 0.020 |
Why?
| | Incidence | 1 | 2017 | 2797 | 0.020 |
Why?
| | Stapes | 1 | 2010 | 24 | 0.020 |
Why?
| | Inflammation | 1 | 2021 | 2835 | 0.020 |
Why?
| | Temporal Bone | 1 | 2010 | 45 | 0.020 |
Why?
| | Graft vs Host Disease | 1 | 1992 | 248 | 0.020 |
Why?
| | Aerosols | 1 | 2011 | 176 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2019 | 2605 | 0.020 |
Why?
| | Administration, Inhalation | 1 | 2011 | 683 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2014 | 2163 | 0.020 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1992 | 288 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 2010 | 1089 | 0.020 |
Why?
| | Graft Survival | 1 | 2011 | 534 | 0.020 |
Why?
| | Chronic Disease | 1 | 2014 | 1786 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2011 | 1507 | 0.020 |
Why?
| | Stents | 1 | 2011 | 528 | 0.020 |
Why?
| | Imaging, Three-Dimensional | 1 | 2010 | 576 | 0.020 |
Why?
| | Ultrasonography | 1 | 2010 | 752 | 0.020 |
Why?
| | Logistic Models | 1 | 2011 | 2067 | 0.020 |
Why?
| | Rats | 1 | 2014 | 5639 | 0.020 |
Why?
| | Signal Transduction | 1 | 2019 | 5077 | 0.020 |
Why?
| | Heart Atria | 1 | 1986 | 137 | 0.010 |
Why?
| | Anti-Bacterial Agents | 1 | 2014 | 1798 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2015 | 5424 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2014 | 4282 | 0.010 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 1991 | 1684 | 0.010 |
Why?
| | Pancreatic Function Tests | 1 | 1981 | 4 | 0.010 |
Why?
| | Exocrine Pancreatic Insufficiency | 1 | 1981 | 21 | 0.010 |
Why?
| | Pregnancy | 1 | 2013 | 6729 | 0.010 |
Why?
| | Somatostatin | 1 | 1980 | 61 | 0.010 |
Why?
| | Middle Aged | 3 | 2019 | 33239 | 0.010 |
Why?
| | Dietary Fats | 1 | 1980 | 304 | 0.010 |
Why?
| | Bromodeoxyuridine | 1 | 1997 | 80 | 0.010 |
Why?
| | Triglycerides | 1 | 1980 | 524 | 0.010 |
Why?
| | Chickenpox | 1 | 1997 | 83 | 0.010 |
Why?
| | Immune Tolerance | 1 | 1997 | 362 | 0.010 |
Why?
| | Herpes Zoster | 1 | 1997 | 316 | 0.010 |
Why?
| | Antibodies, Viral | 1 | 1997 | 624 | 0.010 |
Why?
| | Immunoglobulin G | 1 | 1997 | 887 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 1997 | 2052 | 0.010 |
Why?
| | Bone Marrow Purging | 1 | 1991 | 3 | 0.010 |
Why?
| | Daunorubicin | 1 | 1991 | 26 | 0.010 |
Why?
| | Thioguanine | 1 | 1991 | 19 | 0.010 |
Why?
| | Cytarabine | 1 | 1991 | 61 | 0.010 |
Why?
| | Leukocyte Count | 1 | 1992 | 329 | 0.010 |
Why?
| | Remission Induction | 1 | 1992 | 288 | 0.010 |
Why?
| | Vaccination | 1 | 1997 | 1377 | 0.000 |
Why?
| | Combined Modality Therapy | 1 | 1991 | 1231 | 0.000 |
Why?
| | Fluoresceins | 1 | 1981 | 47 | 0.000 |
Why?
| | Lipase | 1 | 1980 | 69 | 0.000 |
Why?
| | Fatty Acids, Nonesterified | 1 | 1980 | 159 | 0.000 |
Why?
| | Cholesterol | 1 | 1980 | 410 | 0.000 |
Why?
| | Blood Glucose | 1 | 1980 | 2181 | 0.000 |
Why?
| | Insulin | 1 | 1980 | 2406 | 0.000 |
Why?
|
|
Prager's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|